Devil's Claw

A 2026 review published in Frontiers, led by Hong, Lee, Kim and colleagues, examines current evidence for Harpagophytum procumbens in musculoskeletal disorders with a specific comparison against NSAIDs, non-steroidal anti-inflammatory drugs such as ibuprofen that represent the conventional pharmaceutical standard for joint pain and inflammation. Framing a herbal extract's research directly against an established drug class, rather than only against a placebo, is a meaningfully higher evidentiary bar, and it reflects devil's claw's relatively advanced position among herbal anti-inflammatory treatments. A separate 2026 study by Argun, Acer, Kaya, Öz and Çelik examined the anti-inflammatory and cell survival effects of Harpagophytum procumbens extract on ARPE-19 cells, a retinal cell line commonly used in ophthalmological research, testing capsule formulations containing 300 milligrams of extract. This represents research interest extending beyond devil's claw's established joint and arthritis applications into ocular tissue protection, a considerably different area of potential use. A 2026 literature review by Schmidt, covering plants beneficial for arthritis management across osteoarthritis and rheumatoid arthritis, concluded that devil's claw shows genuine promise within this broader plant-based arthritis treatment literature, situating it as one of the more substantiated options reviewed rather than a marginal or under-evidenced entry. This information is provided for educational purposes and does not constitute medical advice. Anyone considering devil's claw for arthritis, joint pain, or any other condition should consult a qualified healthcare professional before use, particularly given the direct comparisons being drawn against established pharmaceutical treatments.

Devil's claw's research profile has historically centred almost entirely on musculoskeletal applications, arthritis and joint pain in particular, supported by decades of the plant's characteristic compound, harpagoside, being studied for anti-inflammatory action in this specific context. A 2026 study by Argun and colleagues breaks from this pattern, testing Harpagophytum procumbens extract on ARPE-19 cells, a retinal pigment epithelium cell line widely used in eye disease research, examining both anti-inflammatory action and cell survival effects at this cellular level. This kind of cross-application research, taking a compound well-established in one therapeutic area and testing it in a completely different tissue type, is a common early step toward identifying unexpected new uses for an already well-characterised plant extract. Retinal cell protection is a genuinely different research question from joint inflammation, even though both may draw on some of the same underlying anti-inflammatory chemistry. Whether this specific line of research develops into anything resembling an ophthalmological product remains to be seen, and a single cell-culture study is an early, preliminary stage of research rather than anything approaching clinical application. What it does demonstrate is that devil's claw's established, well-funded position in arthritis research is creating opportunities for researchers to test the same extract in adjacent fields, leveraging existing extraction and standardisation infrastructure rather than starting research on an entirely unstudied plant.

SANBI's own botanical record lists specific San names for Harpagophytum procumbens, //x'aatataba and tloutaxaba, alongside the Setswana name sengaparile, a naming record that stands out precisely because it exists at all. Colonial disruption of oral tradition means many South African plants lack any preserved San-language name whatsoever, their indigenous naming lost before documentation efforts began, which makes devil's claw's relatively intact record genuinely unusual and worth treating as a valuable, rare piece of preserved knowledge rather than a routine naming footnote. The San and broader Khoisan communities across the Kalahari region, spanning Namibia, Botswana, and South Africa's Northern Cape, hold the deepest traditional knowledge of devil's claw's medicinal properties, knowledge that predates by a considerable margin the plant's twentieth-century emergence as an internationally traded pharmaceutical raw material. The plant's distinctive hooked seed pods, which give it both its English common name and much of its folk recognition, would have been familiar to these communities for generations before any European interest in its medicinal chemistry began. Given how much of devil's claw's current global industry depends directly on wild harvest by San and other indigenous Kalahari communities, this naming record is not merely historical trivia. It is a direct link between the industry's contemporary economic activity and the specific knowledge holders whose generational understanding of the plant underpins the entire trade.

The devil's claw industry across the Kalahari, including in conservancies such as Balyerwa in Namibia, represents an established, functioning example of community-based wild harvest sustaining a substantial international export trade, rather than a smaller-scale or experimental initiative. Communities camp for weeks during the dry season specifically to conduct the harvest, using mother-root-preserving techniques that have apparently sustained the trade at a scale supplying roughly 90 percent of the global market from Namibia alone, over an extended period. This is a genuinely significant operational achievement worth recognising directly. Maintaining a harvest of this commercial scale, entirely from wild populations, without collapsing those populations, requires sustained discipline and genuine ecological knowledge on the part of the harvesting communities, knowledge that is being actively applied at scale rather than existing only in theory or academic documentation. Germany's position as the dominant buyer for dried devil's claw tubers indicates a well-established, mature export relationship, one that has evidently supported continued investment in the kind of sustainable harvest infrastructure and community organisation, such as the Balyerwa Conservancy model, that keeps this trade viable. Whether similar conservancy-based models could be extended more formally to South Africa's own Northern Cape and North West devil's claw populations is worth exploring as a potential development, given the shared ecological and cultural context across this Kalahari-spanning trade.

Devil's claw occupies a distinctive position among South Africa's indigenous medicinal plants: a mature, high-volume export trade, supplying European pharmaceutical and veterinary markets at a scale supporting thousands of Kalahari harvesters, with Germany established as the dominant buyer for dried tubers. This level of market maturity, decades in the making, gives devil's claw considerably more established trade infrastructure than most other plants covered in this registry, most of which remain at earlier stages of export development. The near-term intelligence picture for anyone sourcing or trading in devil's claw centres less on demand uncertainty, which appears well established, and more on regulatory direction. Recent moves toward stricter export controls and formal Access and Benefit-Sharing requirements, echoing the precedent set by the Hoodia agreement, suggest buyers should expect increasing documentation and compliance requirements around harvester compensation and traceability, rather than assuming the historical, less formally regulated trade pattern will continue unchanged. For South African participants specifically, given devil's claw's occurrence in the Northern Cape and North West provinces alongside the much larger Namibian trade, aligning early with whatever Access and Benefit-Sharing standards emerge from the broader Kalahari-wide regulatory conversation is likely to matter more for long-term market access than production volume alone. This is market observation based on currently available regulatory and industry documentation, not investment advice, and any commercial decision should involve independent legal and financial guidance given the plant's cross-border regulatory complexity.

Devil's claw's international trade operates under increasing regulatory attention given its dependence on wild harvest at a scale supporting roughly 90 percent of global supply from Namibia alone. Recent regulatory developments mandate stricter export controls and formal Access and Benefit-Sharing frameworks specifically aimed at ensuring fairer compensation reaches the indigenous collectors, largely San and rural Kalahari communities, whose labour and traditional knowledge underpin the entire trade. This regulatory direction echoes the precedent set by the Hoodia case, another San-linked South African plant where a formal benefit-sharing agreement was established following earlier commercial exploitation without adequate recognition of San traditional knowledge. Devil's claw's situation shares meaningful similarities: a plant with deep San traditional use, now supporting a substantial international pharmaceutical and veterinary market, where the question of whether commercial value adequately flows back to the original knowledge holders and harvesters remains an active, ongoing policy concern rather than a settled matter. Within South Africa, devil's claw's presence on the SANBI Red List of South African Plants, alongside its occurrence in the Northern Cape and North West provinces, means domestic conservation and access regulation applies alongside whatever broader Access and Benefit-Sharing frameworks govern the wider, largely Namibia-centred international trade.